# A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People

> **NCT05046873** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 16 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Co-formulation NNC0480 0389+Semaglutide A 10/1 mg/mL
- **DRUG:** semaglutide 1.34 mg/mL (placebo)
- **DRUG:** Semaglutide 1.34 mg/mL
- **DRUG:** NNC0480-0389 A 10 mg/mL

## Key facts

- **NCT ID:** NCT05046873
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-06
- **Primary completion:** 2022-01-05
- **Final completion:** 2022-01-05
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2023-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05046873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05046873, "A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT05046873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*